Cassava Sciences(SAVA) - 2025 Q1 - Quarterly Results

EXHIBIT 99.1 Simufilam for TSC-related epilepsy Simufilam is a proprietary, investigational oral small molecule that targets the filamin A protein Cassava Reports Q1 2025 Financials Results, Provides Business Update License agreement and recent leadership appointments position Cassava to advance development of simufilam in TSC-related epilepsy $117.3 Million in Cash and Cash Equivalents at March 31, 2025 AUSTIN, Texas, May 08, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Co ...